|
|
Vaccine Detail
|
WT1 126-134 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: WT1 126-134 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007057
- Type: Peptide Vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: WT1 (NCIT_C61442)
- WT1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Peptides were synthesised using standard Fmoc chemistry (Brooks et al., 2015).
- Description: This is for Leukemia Cancer and Liver Cancer (NCT01842139). A synthetic peptide vaccine consisting of the amino acids 126 through 134 of the human Wilms' Tumor protein-1 (WT1) with potential antitumor activity. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. Vaccination with WT1 126-134 peptide vaccine may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation (Brooks et al., 2015; NCIT_C61442).
|
| Host Response |
|
|
| References |
Brooks et al., 2015: Brooks SE, Bonney SA, Lee C, Publicover A, Khan G, Smits EL, Sigurdardottir D, Arno M, Li D, Mills KI, Pulford K, Banham AH, van Tendeloo V, Mufti GJ, Rammensee HG, Elliott TJ, Orchard KH, Guinn BA. Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. PloS one. 2015; 10(10); e0140483. [PubMed: 26492414].
NCIT_C61442: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61442]
NCT01842139: [https://clinicaltrials.gov/show/NCT01842139/]
|
|
